The Effect of Deep Oscillation Therapy in Fibrocystic Breast Disease. A Randomized Controlled Clinical Trial
Introduction: Fibrocystic breast disease is the most widespread disorder in women during their phase of sexual maturity. Deep oscillation (DO) therapy has been used on patients who have undergone an operation for breast cancer as a special form of manual lymphatic drainage.
Method: Experimental, prospective case-control studies were conducted in 401 women diagnosed with fibrocystic breast disease. The sample was selected at random and was divided into three groups, a study group and two control groups.
Results: Pain was reduced in the three therapies applied. This was statistically significant in the study group. The sonography study presented a predominance of its fibrous form. Upon completion of the treatment a resolution of the fibrosis was observed in the study group. The women were using their bra in an incorrect manner.
Conclusions: Pain was reduced in the three therapies applied. In the study group this reduction was statistically significant. It is possible to verify the magnitude of the resonant vibration in the connective tissue from surface to deep layers by viewing the effect of the deep oscillations through the use of diagnostic ultrasound. The most frequent sonographic finding was fibrosis. Deep oscillation therapy produces a tissue-relaxing, moderate vasoconstriction effect, favours local oedema reabsorption and fibrosis reduction. A factor that may affect breast pain is incorrect bra use. The majority of women studied were using their bra incorrectly.
2 Okolowsky N, Furth PA, Hamel PA. Oestrogen receptor-alpha regulates non-canonical Hedgehog-signalling in the mammary gland. Dev Biol. 2014 Jul. 15;391(2):219-29. doi: 10.1016/j.ydbio.2014.04.007. Epub 2014 Apr 21.
3 Zendehdel M, Niakan B, Keshtkar A, Rafiei E, Salamat F. Subtypes of Benign Breast Disease as a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis Protocol. Iran J Med Sci. 2018 Jan;43(1):1-8. Available in: https://www.ncbi.nlm.nih.gov/pubmed/29398746)
4 Pereira MA, Segura ME, Santos AM, Casulari LA. Regression of the fibrous disease of the breast in a non-diabetic woman after pregnancy and breastfeeding. Arq Bras Endocrinol Metabol. Dec; 2007, 51(9):1539-43.
5 Park JH, Chun M, Jung YS, Bae SH. Predictors of Psychological Distress Trajectories in the First Year After a Breast Cancer Diagnosis. Asian Nurs Res (Korean Soc Nurs Sci). 2017 Dec;11(4):268-275 Available in: https://www.ncbi.nlm.nih.gov/pubmed/29290274
6 Johannsen M, Frederiksen Y, Jensen AB, Zachariae R. Psychosocial predictors of posttreatment pain after nonmetastatic breast cancer treatment: a systematic review and meta-analysis of prospective studies. J Pain Res. 2017 Dec 21;11:23-36. Available in: https://www.ncbi.nlm.nih.gov/pubmed/29317846
7 Langford DJ, Schmidt B, Levine JD, Abrams G, Elboim C, Esserman L, et al. J Pain Symptom Manage. 2014 Dec 16. pii: S0885-3924(14)00915-4. doi: 10.1016/j.jpainsymman.2014.11.292.
8 Rodríguez Pérez A., Castell Moreno J. Afecciones mamarias (Breast Conditions). Havana: Editorial Ecimed; 2010. Chap. 3. p. 48-99.
9 Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, Ginsberg M, et al. A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control. 2010;21:821---8.
10 Pailoor K, Fernandes H, Cs J, Marla NJ, Keshava S M. Fine needle aspiration cytology of male breast lesions - a retrospective study over a six year period. J Clin Diagn Res. 2014 Oct;8(10):FC13-5. doi: 10.7860/JCDR/2014/10708.4922. Epub 2014 Oct 20.
11 Rinaldi P, Lerardi C, Costantini M, Magno S, Giulani M,Belli P, et al. Cystic breast lesions: sonographic findings and clinical management. J Ultrasound Med. 2010;29:1617- 26
12 Destounis S, Arieno A, Morgan R. New York State Breast Density Mandate: Follow-up Data With Screening Sonography. J Ultrasound Med. 2017 Dec;36(12):2511-2517. doi: 10.1002/jum.14294. Epub 2017 Jun 28. Available in: https://www.ncbi.nlm.nih.gov/pubmed/28656638
13 Kumar S, Rai R, Agarwal GG, Dwivedi V, Kumar S, DAS V. A randomized, double-blind, placebo-controlled trial of ormeloxifene in breast pain and nodularity. Natl Med J India. 2013 Mar-Apr;26(2):69-74.
14 Carauleanu A, Socolov R, Rugina V, Gabia O, Carauleanu DM, Lupascu IA, Socolov D. Comparisons between the non-proliferative and proliferative therapy in fibrocystic mastosis. Rev Med Chir Soc Med Nat Iasi. 2016 Apr-Jun;120(2):321-7. Available in: https://www.ncbi.nlm.nih.gov/pubmed/27483712
15 Mainero Ratchelous E, Aguilar Gallegos I, Pedraza Barajas S, Vargas Hernández VM. Guias de prácticas clínicas. Tratamiento de la mastalgia (Guide to Clinical Practices. Treatment of Mastalgia). Ginecol Obstet Mex; 2009, 77(12):S371-S390
16 Deschamps M1, Band PR, Coldman AJ, Hislop TG, Longley DJ. Clinical determinants of mammographic dysplasia patterns. Cancer Detect Prev. 1996; 20(6):610-9.
17 Gallo Vallejo JL, Mas Masats MP, Vico Zúniga I, Aibar Villánd L. Mastopatía fibroquística. Aspectos controvertidos (Fibrocystic Mastopathy. Controversial Aspects). Clin Invest Gin Obst.2013. Available in: http://dx.doi.org/10.1016/j.gine.2013.02.006
18 Hernández Tápanes S. Cáncer de Mama y Medicina de Rehabilitación. Avances y perspectivas. Actas del 8vo Congreso de la Sociedad Internacional de Medicina Física y Rehabilitación (Breast Cancer and Rehabilitative Medicine. Advances and Perspectives. Proceedings of the 8th Congress of the International Society of Physical and Rehabilitation Medicine); 2014 Jun 1-5; Cancun, Mexico
19 Reinhold J, Deeva I, Korkina L, Schaper K, Krummenauer F. Randomised pilot study for quantification of benefit from the patient's point of view of deep oscillation treatment in primary wound healing. Orthop Unfall. 2014 Jun;152(3):260-4. doi: 10.1055/s-0034-1368447. Epub 2014 Jun 24.
20 Fistetto G, Iannitti T, Capone S, Torricelli F, Palmieri B. Deep Oscillation: therapeutic-rehabilitative experiences with a new electrostatic device. Minerva Med. 2011 Aug;102(4):277-88.
21 Reißhauer, A, Schoppe B, Jahr S. Evaluation of the effect of Deep Oscillation (HIVAMAT 200) on tissue changes of the breast in patients with secondary breast lymphedema. European Journal of Lymphology 2007 17(30): 51.
22 Dyrstad SW, Yan Y, Fowler AM, Colditz GA.Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat. 2015 Jan 31
23 Ramos Águila Y, Marimón Torres E R, Crespo González C, Junco Sena B, Valiente Morejón W. Cáncer de mama, su caracterización epidemiológica. Rev Ciencias Médicas [Internet]. 2015 Ago [citado 2018 Feb 11] ; 19( 4 ): 619-629. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-31942015000400006&lng=es
24 Santen RJ. Benign Breast Disease in Women. [Updated 2017 Jan 11]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available in: https://www.ncbi.nlm.nih.gov/books/NBK278994/
25 Vessey M, Yeates D. Oral contraceptives and benign breast disease: an update of findings in a large cohort study. Contraception. 2007; Dec; 76(6):418-24
26 Gadducci A, Guerrieri ME, Genazzani AR. Benign breast diseases, contraception and hormone replacement therapy. Minerva Ginecol. 2012 Feb; 64(1):67-74.
27 Santen J, Mansel R. Benign Breast Disorders Richard N Engl J Med 2005; 353:275-285 July 21, 2005DOI: 10.1056/NEJMra035692. Available in: http://www.nejm.org/doi/full/10.1056/NEJMra035692
28 Ramírez, JMR. Displasia mamaria, manifestaciones clínicas y algunos aspectos de su tratamiento actual. MEDISAN [Internet]. 2014;18(7):152-156. Available in: http://www.redalyc.org/articulo.oa?id=368445165019
29 Schönfelder G, Berg D. Nebenwirkungen nach brusterhaltender therapie des mammakarzinoms. Erste Ergebnisse mit Hivamat.1991; Gynäkol. Prax. 15, 109-122.
30 Gao Y C, Peng C C, Peng R Y. A long term chronic fibrotic adhesion of elbow muscles alleviated by applying Hivamat 200 deep oscillation therapy. International Journal of Multidisciplinary Research and Development 2015 2(1), 286-289.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright policies & self-archiving
We are a RoMEO green journal.
Author's Pre-print: author can archive pre-print (ie pre-refereeing)
Author's Post-print: author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: author can archive publisher's version/PDF
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 4.0 License ©